Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 52: 171-181, 2006. First published December 8, 2005; 10.1373/clinchem.2005.058560
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2005.058560v1
52/2/171    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (20)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bossuyt, X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bossuyt, X.
Related Collections
Right arrow Clinical Immunology
(Clinical Chemistry. 2006;52:171-181.)
© 2006 American Association for Clinical Chemistry, Inc.

Review

Serologic Markers in Inflammatory Bowel Disease

Xavier Bossuyt

1 Laboratory Medicine, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium. Fax 32-16-347931; e-mail Xavier.Bossuyt{at}uz.kuleuven.ac.be.

Inflammatory bowel disease (IBD) is an enduring disease involving mostly young people, with symptoms of bloody diarrhea and abdominal cramps. Several antibodies have been associated with IBD, the 2 most comprehensively studied being autoantibodies to neutrophils (atypical perinuclear anti-neutrophil cytoplasmic antibodies) and anti-Saccharomyces cerevisiae antibodies. This review focuses on the value of these antibodies for diagnosing IBD, differentiating Crohn disease from ulcerative colitis, indeterminate colitis, monitoring disease, defining clinical phenotypes, predicting response to therapy, and as subclinical markers. Pancreatic antibodies and newly identified anti-microbial antibodies (anti-outer membrane porin C, anti-I2, and anti-flagellin) are also reviewed.




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
N. Vermeulen, I. Arijs, S. Joossens, S. Vermeire, S. Clerens, K. Van den Bergh, G. Michiels, L. Arckens, F. Schuit, L. Van Lommel, et al.
Anti-{alpha}-enolase Antibodies in Patients with Inflammatory Bowel Disease
Clin. Chem., March 1, 2008; 54(3): 534 - 541.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
L. Henckaerts, M. Pierik, M. Joossens, M. Ferrante, P. Rutgeerts, and S. Vermeire
Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease
Gut, November 1, 2007; 56(11): 1536 - 1542.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
M. Ferrante, L. Henckaerts, M. Joossens, M. Pierik, S. Joossens, N. Dotan, G. L Norman, R. T Altstock, K. Van Steen, P. Rutgeerts, et al.
New serological markers in inflammatory bowel disease are associated with complicated disease behaviour
Gut, October 1, 2007; 56(10): 1394 - 1403.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Association for Clinical Chemistry.